These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Pharmacokinetics of TZU-0460, a new H2-receptor antagonist, in patients with impaired renal function.
    Author: Takabatake T, Ohta H, Yamamoto Y, Ishida Y, Hara H, Nakamura S, Ushiogi Y, Satoh S, Hattori N.
    Journal: Eur J Clin Pharmacol; 1986; 30(6):709-12. PubMed ID: 2876900.
    Abstract:
    We have studied pharmacokinetics of a new H2-receptor antagonist, TZU-0460, in patients with varying degrees of renal impairment. The apparent volume of distribution at steady-state was 1.70 l/kg, and the plasma protein binding of TZU-0460 or its active metabolite, desacetyl TZU-0460 was less than 10% in normal subjects. These variables were not altered with renal impairment. Sixty percent of TZU-0460 given orally was excreted via the kidney, mainly by tubular secretion. The half-time of elimination was 3.94 h in normal subjects, and was prolonged to 12.13 h in severe renal failure (creatinine clearance below 30 ml/min/1.48 m2). Dosage adjustment of TZU-0460 is necessary in renal failure.
    [Abstract] [Full Text] [Related] [New Search]